A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2018
At a glance
- Drugs Brolucizumab (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms KITE
- Sponsors Novartis Pharmaceuticals
- 18 Jun 2018 Planned initiation date changed from 1 Jul 2018 to 2 Aug 2018.
- 13 Jun 2018 Planned initiation date changed from 29 Jun 2018 to 1 Jul 2018.
- 04 Apr 2018 New trial record